Neurocompute scores biomedical literature, surfaces overlooked patterns, and turns Parkinson’s research into a living discovery terminal.
C grade · PMID 41946390
View analysis →C grade · PMID 42022552
View analysis →C grade · PMID 41902900
View analysis →C grade · PMID 41995105
View analysis →C grade · PMID 41951427
View analysis →C grade · PMID 41934064
View analysis →C grade · PMID 41981240
View analysis →C grade · PMID 41943176
View analysis →C grade · PMID 41986378
View analysis →C grade · PMID 41925724
View analysis →In a rotenone rat model of Parkinson's disease, the hemoglobin-derived peptide LVV-H3 reduced calcineurin activity in brain, spinal cord, lymphoid organs and plasma and partially normalized altered IL-2 and TNFα levels, effects that overlapped but were not identical to the calcineurin inhibitor…
By demonstrating that an endogenous peptide can modulate calcineurin signaling and peripheral/CNS cytokine profiles in a mitochondrial toxin PD model, this study identifies a biologically plausible, targetable mechanism (CaN-driven inflammation) with translational potential for early-stage PD…
This review compiles preclinical and limited clinical evidence that luteolin, a dietary flavonoid, can reduce neuroinflammation, oxidative stress, and pathological protein aggregation (including α-synuclein) and improve cognitive and motor outcomes in models of neurodegeneration, but its…
It identifies actionable, PD-relevant mechanisms (NF-κB/MAPK anti-inflammatory effects, Nrf2 antioxidant activation, BDNF-related synaptic support, and mitigation of α-synuclein aggregation) that support luteolin as a repurposing/formulation target for neuroprotective strategies in Parkinson's…
Review synthesizing evidence that dysregulated dietary lipids and lipid-mediated signaling impair neurovascular unit components—via oxidative stress, inflammation, BBB disruption, mitochondrial and neurotransmitter dysfunction—and linking these mechanisms to Alzheimer's and Parkinson's disease…
Identifies modifiable lipid-related pathways (diet, BBB integrity, inflammation, mitochondrial dysfunction) that are relevant to PD therapeutic discovery and biomarker development, offering translational hypotheses despite being largely conceptual and needing experimental validation.
This pilot study reports a significant reduction in peripheral ND3 mitochondrial DNA copy number in progressive supranuclear palsy (PSP) patients versus age-matched controls, with changes largely independent of chronological aging and suggestive phenotype trends.
By implicating systemic mitochondrial impairment measurable in blood, the work supports mitochondria-targeted biomarker and therapeutic strategies that could be relevant to Parkinson’s disease research, though results are preliminary and specific to PSP.
This 3T MRI study shows that frontal cortical T2* hypointensity (likely reflecting iron accumulation/neuroinflammation) is ubiquitous in corticobasal syndrome, rarer in PSP, and its regional distribution correlates with specific motor and language deficits.
Provides a noninvasive imaging biomarker linking iron/inflammation topography to clinical phenotype in 4‑repeat tauopathies, aiding patient stratification, diagnostic accuracy, and mechanistic or therapeutic targeting of neuroinflammation/iron-related pathology.
Review of CAR-T cell therapy for autoimmune neurological diseases that highlights both therapeutic promise (especially B-cell–targeted approaches) and significant neurotoxicities including ICANS and movement disorders such as parkinsonism.
Offers useful perspectives on immune-reprogramming strategies and neuroinflammation that could inform Parkinson's immunotherapies, while flagging crucial safety risks (neurotoxicity/parkinsonism) relevant for translating cell-based approaches to PD.
Treating Parkinson's patient neurons with myristic acid (C14:0) remodels membrane lipid composition, reduces pathogenic α-synuclein membrane association, lowers Lewy-like inclusions and pSer129, and restores tetramer:monomer balance, with NMR showing decreased membrane dwell time and aggregation…
Provides a clear, actionable mechanism—lipid remodeling via C14:0—that reverses α-synuclein pathogenic phenotypes in patient neurons and offers a plausible translational path for lipid-based or metabolic therapies in PD.
This study reports that DAPK1 phosphorylates parkin at Ser136 and Ser198, promoting its mitochondrial translocation and MITOL-dependent degradation, which reduces parkin levels and increases neuronal vulnerability to 6-OHDA toxicity.
By defining a DAPK1→parkin→MITOL pathway that links mitochondrial dysfunction to reduced parkin-mediated neuroprotection, the work highlights DAPK1 inhibition or preservation of parkin as actionable therapeutic strategies for Parkinson's disease.
In C. elegans, tissue-specific loss of pink-1 causes neuronal dysregulation of dgk-1 that impairs defecation rhythm and intestinal pink-1 loss that suppresses glutathione metabolism, together promoting pathogenic gut colonization and ROS-driven dopaminergic neurodegeneration, with aspects conserved…
By linking PINK1 to gut-brain interactions, glutathione-dependent redox failure, and a defined neuronal transcriptional pathway, this study reveals actionable targets (antioxidant/glutathione pathways, gut microbial control, and DGK-related signaling) for therapeutic exploration in PD despite the…
LRRK2 activity and glucocerebrosidase modulate cellular bis(monoacylglycerol)phosphate (BMP) levels and the release of BMP-enriched extracellular vesicles, and LRRK2 kinase inhibition partially normalizes these changes in fibroblasts and MEFs.
Links two major PD-relevant pathways (LRRK2 and GCase/lysosomal lipid handling) to a drug-modifiable EV-associated biomarker (BMP-positive EVs), offering mechanistic insight and translational leads for diagnostics and therapies targeting lysosomal dysfunction in Parkinson's.
The authors report two membrane-permeable, aggregation-induced-emission oxazolidine probes (OX1/OX2) that turn on red fluorescence upon binding amyloid fibrils, detect intracellular α-synuclein and insulin aggregates, and — per docking—show stronger fibril binding (OX2) than ThT.
By enabling sensitive intracellular and red-shifted detection of α-synuclein assemblies with low cytotoxicity, these probes are valuable tools for studying aggregation kinetics, cellular pathology, and for screening or validating therapeutics and biomarkers relevant to Parkinson's disease.
A focused review of CRISPR-Cas tools (CRISPR-Cas9, base and prime editing) applied to Parkinson's disease research and modeling, covering correction of SNCA, LRRK2 and PINK1 mutations, generation of iPSC/isogenic/transgenic models, and translational challenges.
It synthesizes actionable genome‑editing approaches and preclinical models that directly inform development of targeted, potentially disease‑modifying therapies for PD while outlining key barriers to clinical translation.
This systematic review of N-acetylcysteine (NAC) across seven neurological disorders reports favorable safety and limited but promising PD-specific signals—most notably combined IV/oral NAC improving dopamine transporter binding—while noting small study sizes, high risk of bias, and sparse…
NAC is a well-tolerated, mechanistically plausible glutathione precursor that shows preliminary dopaminergic biomarker effects in PD, supporting prioritized, well-powered randomized trials with standardized oxidative stress and dopaminergic biomarker endpoints for therapeutic repurposing.
Preliminary study found ten sessions of bilateral DLPFC tDCS in PD patients with mild-to-moderate depression improved mood, apathy, UPDRS III motor scores, and increased daily step counts measured by wearable bands, with step-count gains strongly correlating with reduced apathy.
Indicates a translatable, nonpharmacological intervention that may enhance goal-directed motor behavior via mood/apathy modulation and uses objective wearable measures for functional readouts, though it lacks molecular disease‑modifying mechanism data.
This perspective synthesizes evidence that dysregulated fatty acid and oxylipin metabolism alters alpha-synuclein–membrane interactions and may contribute to PD, proposing the oxylipin-ome as a source of biomarkers and disease-modifying targets.
By linking PUFA/oxylipin dysregulation, inflammation (COX pathways), and alpha-synuclein biology, the paper identifies a mechanistically plausible, targetable lipid-inflammatory axis with biomarker potential and actionable translational leads (e.g., PUFA modulation, COX-related interventions) for…
Narrative review synthesizing evidence that exocrine gland dysfunction in Parkinson's disease reflects central and peripheral autonomic and glandular alpha-synuclein pathology, can precede motor symptoms, and surveys diagnostic methods and management approaches.
Identifies accessible peripheral exocrine tissues as potential prodromal biomarkers and windows into autonomic alpha-synuclein pathology that could aid early diagnosis and patient stratification, offering translational value despite limited direct novel molecular targets for drug development.
Preclinical autoradiography and PET studies reveal [18F]asyn-44 and ACI-12589 target different α‑synuclein sites, but asyn-44 shows low specificity and species-dependent rapid metabolism (problematic in NHPs) and ACI-12589 exhibits off-target amyloid‑β binding.
Although neither tracer is immediately translatable, the negative and comparative data clarify tracer selectivity, off-target liabilities, and species metabolic differences that are directly actionable for designing better α‑synuclein PET ligands to support Parkinson's therapeutic development and…
In a 10-year longitudinal study of 405 early-stage, drug‑naive PD patients, higher baseline serum IGF‑1 was associated with a slower progression of anxiety symptoms, with middle and high tertiles showing significantly reduced anxiety worsening over time.
While observational and lacking mechanistic detail, the result highlights IGF‑1 as a promising prognostic biomarker and a candidate pathway for developing neuroprotective or symptom‑modifying interventions targeting non‑motor features in PD.
Systematic review (2000–2025) of preclinical and clinical studies summarizing neuroprotective plant extracts in PD, highlighting antioxidant, anti-inflammatory, anti-α‑synuclein, dopaminergic neuron–protective, and synaptic-restorative mechanisms.
Aggregates mechanistic evidence that plant extracts can target inflammation, oxidative stress and α‑synuclein—areas of high therapeutic interest for disease modification—while flagging important translational gaps (heterogeneity, standardization, dosing, bioavailability) that limit immediate…
Randomized controlled protocol testing repeated lower-extremity hot water bathing (daily 30-min sessions for 4 weeks) versus usual care in 40 elderly patients with advanced Parkinson's disease to evaluate safety and effects on sleep using PDSS and polysomnography.
Sleep is an important non-motor symptom in PD; this trial evaluates a low-cost, non-pharmacologic rehabilitative approach with objective sleep outcomes and safety data that could inform larger, pragmatic trials and offer a new symptomatic management option.
